Selank side effects have two different answers, and which one applies depends entirely on what is in front of you. Inside Russia, this is a registered medicine, which means a regulator assessed a safety dossier and approved prescribing information containing the known adverse effects for an approved indication. That is a real safety record, produced the way safety records are produced.
The vendor we point lifters to
Selank from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 21, 2026.
Outside Russia, none of that applies to the vial someone actually bought. There is no marketing authorisation from the FDA, the EMA or the MHRA, no Western trial has ever been registered, and the product in circulation is a research chemical whose identity and purity are attested by the seller.
Both statements are true at once, and most writing about this compound picks one and drops the other.
The Selank side effects question has a jurisdiction problem
Regulatory approval is not a certificate that travels with a molecule. It is a decision about a specific manufactured product, made for a specific indication, on the basis of a specific dossier, by a specific agency. When the same chemical is synthesised elsewhere and sold as a research reagent, the approval does not extend to it in any sense.
This creates a peculiar situation for a reader. The safety information that exists is real, and it describes a product they are almost certainly not using. Meanwhile the product they are using has no safety information at all, and its risks include ones the approved medicine does not have, because they come from the supply chain rather than the compound.
Treating a Russian approval as reassurance for an internet purchase mixes those two things together. So does dismissing the approval as meaningless. The correct position is that a safety record exists in one system, for one product, and that it says nothing about a vial of unverified powder.
What the profile claims rest on
The characterisation attached to this peptide in Russian clinical work is that it reduces anxiety symptoms in patients with anxiety disorders without the sedation and dependence associated with benzodiazepines, including in studies comparing the two.
That is worth taking seriously as clinical literature and worth flagging accurately. It is a description from one evidence system. No FDA, EMA or MHRA assessment has examined it, no genuine Western trial has tested it, and a claim of absent dependence liability is exactly the sort of claim that historically has required long observation to confirm.
It is also worth being clear about what an approved label contains and what it does not. It lists adverse effects observed at approved doses, in the treated population, over the studied period. It says nothing about other doses, other routes, healthy people, or longer exposures, and those are exactly the conditions under which the compound is used outside a clinic.
The preclinical picture is neurochemical. Rat studies have reported effects on brain serotonin metabolism and on expression of brain derived neurotrophic factor. Laboratory work in human plasma has described slowed breakdown of endogenous enkephalins. These findings support an anxiolytic mechanism. They do not constitute a safety dataset, and animal neurochemistry is not designed to detect the effects that concern a person taking something for months.
Direct answers before going further
Are Selank side effects documented anywhere?
Yes, in approved Russian prescribing information for its registered indication, and in that country's clinical literature. Nothing comparable exists in the Western record, because no Western trial has been conducted.
Does the absence of Western reports mean it is well tolerated?
No. It means no Western structured collection exists. An empty record and a clean record look identical from a distance and mean opposite things.
Could it interact with medication?
No interaction studies are available in the Western literature for this compound. Anyone taking psychiatric medication is combining an unstudied substance with a prescribed one, which is a conversation for a doctor rather than a forum.
Is it risky during hard training?
Unknown. No study in any species has administered this peptide to trained subjects, alongside exercise, or measured alertness, arousal or performance during training.
What is the largest practical risk?
For most buyers outside Russia, the contents of the vial. Identity, purity, sterility and quantity are unverified, and injecting a non sterile preparation carries risk unrelated to the molecule.
The risks that come from the supply chain
This is the part that gets least attention and deserves most, because it applies regardless of what the peptide does.
A research chemical is manufactured without an inspected pharmaceutical standard, released without regulator reviewed batch testing, and sold without recall machinery if something is wrong. A vial may contain less than stated, more, degraded material, or impurities from synthesis. Sterility is asserted rather than demonstrated. Storage and reconstitution add further variability, since peptides in solution degrade at rates that depend on handling.
There is also a route mismatch specific to this compound. The registered Russian product is intranasal. Much of the online discussion concerns injection, which introduces sterility and technique risks the approved formulation does not have, and does so with no published data on what that route does with this peptide in humans.
A third party certificate of analysis narrows the uncertainty without closing it, because it describes a batch at the time of testing rather than the vial that arrived.
One detail is specific to this compound and worth separating out. Because a regulated version genuinely exists in Russia, buyers sometimes assume the material they receive is that product reaching them through another channel. There is no basis for that assumption, and labelling on a research chemical is not evidence of origin.
What is known about stopping
A question that gets skipped entirely: what happens on discontinuation.
For benzodiazepines that question has a large and unpleasant literature in humans, which is exactly why the comparison with this peptide is drawn in the first place. The Russian clinical characterisation describes an absence of dependence, and that description belongs to that literature rather than to any independent review of it.
Outside Russia there is nothing at all. No withdrawal study, no rebound study, no follow up of people who stopped after extended use, in any species. Somebody using it for months has no published basis for predicting what stopping is like, and an absence of reports is not an absence of effects when nobody has been looking.
Why a compound acting on the nervous system deserves more caution, not less
There is a tendency to treat a substance with mild described effects as low stakes, and for something acting on the nervous system that reasoning runs backwards.
The described mechanism involves serotonin metabolism in rats and endogenous signalling peptides in laboratory work in human plasma. Systems of that kind are the target of a large share of prescribed medication, and interactions between agents acting on them are a routine clinical concern. No interaction data for this peptide exists in the Western literature.
Then there is self diagnosis. Anxiety severe enough to justify treatment is a clinical judgement, and the same symptoms accompany conditions that need entirely different management. Buying an unapproved anxiolytic online substitutes a purchase for that judgement, at the point when a person is least well placed to make it.
Where each concern actually stands
| Concern | Best available information | Which system it comes from | Organism |
|---|---|---|---|
| Adverse effects at approved use | Documented in approved prescribing information | Russian regulatory | Human |
| Dependence and sedation | Described as absent in Russian clinical work, not independently reviewed | Russian clinical | Human |
| Long term use outside the indication | Nothing published | None | None |
| Interaction with psychiatric medication | Nothing published in the Western record | None | None |
| Use during heavy training | Nothing published | None | None |
| Effects on muscle or body composition | Never measured in any study | None | None |
| Neurochemical effects | Serotonin metabolism, BDNF expression | Preclinical | Rat |
| Contamination, dosing error, non sterile injection | A property of unregulated supply | Practical | Human |
| Anti doping status | Non approved substances are prohibited at all times | Sport regulatory | Human |
The row with no measurement at all is the one this site's readers should notice. Body composition has never been an outcome in any study of this peptide, so there is no benefit on that side of the ledger to weigh any risk against.
Two decisions this actually affects
Two things are concrete enough to act on.
The first is competitive. Standard anti doping rules prohibit non approved substances at all times, and a compound without marketing authorisation in the athlete's jurisdiction falls into that category. Whether it appears on a routine panel is a different question from whether using it breaks the rules.
The second is a matter of proportion. If anxiety or poor sleep is genuinely degrading training, that is a real problem worth solving, and the treatments with substantial evidence in an accessible system come from a clinician. Substituting an unregulated vial for that conversation trades a documented risk profile for an undocumented one, in pursuit of a body composition benefit that no study has ever demonstrated in any organism.